These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3106756)

  • 21. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
    Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
    Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
    Saxenhofer H; Weidmann P; Riesen WF; Beretta-Piccoli C; Fragiacomo C; Wunderlin R; Noseda G
    Eur J Clin Pharmacol; 1990; 39(2):101-5. PubMed ID: 2123791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia.
    Weisweiler P; Merk W; Janetschek P; Schwandt P
    Atherosclerosis; 1984 Dec; 53(3):321-5. PubMed ID: 6529448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS.
    Gaddi A; Arca M; Ciarrocchi A; Fazio S; D'Alò G; Tiozzo R; Descovich GC; Calandra S
    Metabolism; 1991 Oct; 40(10):1074-8. PubMed ID: 1658544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia.
    Hoeg JM; Maher MB; Zech LA; Bailey KR; Gregg RE; Lackner KJ; Fojo SS; Anchors MA; Bojanovski M; Sprecher DL
    Am J Cardiol; 1986 Apr; 57(11):933-9. PubMed ID: 3515897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
    Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
    Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin.
    Lijnen P; Celis H; Desager JP; Fagard R
    J Hum Hypertens; 1995 Jul; 9(7):557-64. PubMed ID: 7562885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
    Fusegawa Y; Tada H; Oguma T; Shiina Y; Moriguchi EH; Tanabe T; Tamachi H; Tomoda H; Goto Y
    Tokai J Exp Clin Med; 1993 Dec; 18(3-6):81-6. PubMed ID: 7701533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
    Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
    Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia.
    Wakatsuki A; Okatani Y; Ikenoue N
    Atherosclerosis; 2000 May; 150(1):103-11. PubMed ID: 10781640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia.
    Grundy SM; Vega GL; Bilheimer DW
    Ann Intern Med; 1985 Sep; 103(3):339-43. PubMed ID: 3849281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia.
    Schwandt P; Weisweiler P
    Atherosclerosis; 1980 Mar; 35(3):301-6. PubMed ID: 6987993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.